Last Published:  07/30/20 02:45:15 PM (Central)
Short Title: Cross Risk Countermeasures II
Responsible HRP Element: Space Radiation
Collaborating Org(s):
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
Solicited
Aims:

Research will evaluate medical countermeasures that mitigate risk of radiation induced diseases addressing multiple tumor types and multiple risk areas (i.e., cancer, late neurodegeneration, cardiovascular disease) including the:

 

  • Mitigation of solid and hematologic cancers due to space radiation exposure as measured by incidence, aggressiveness, overall burden, and time to occurrence.

 

  • Mitigation of cardiovascular disease incidence, latency, and progression as measured by clinical outcomes, events, pathology and survival times.

     

  • Mitigation of late neurodegenerative conditions and microvascular disruption of the CNS as measured by changes in performance, cognitive function, and pathology.

 

Specific Aims:

 

  • Aim 1 (Cross Risk): Identify and prioritize candidate cross-risk countermeasure agents targeting common pathways of adverse outcomes from space radiation exposure

  • Aim 2 (Cross Risk): Using appropriate animal models, test efficacy of selected medical countermeasures for prevention of adverse outcomes across multiple risk areas following simulated GCR and SPE exposures.

  • Aim 3 (Cross Risk): Identify potential cross-risk and cross-element antagonistic countermeasure approaches

  • Aim 4 (Cross Risk): Identify biomarker approaches to assess countermeasure efficacy for surveillance, treatment, and outcome prediction.


Resources (None Listed)
Mappings
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
You are here!TaskCenter for Medical Countermeasures II – Cross Risk

RiskRisk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
GapBMed-102: Given exposures to spaceflight hazards (space radiation, isolation), how do we identify individual susceptibility, monitor molecular/biomarkers and acceptable thresholds, and validate behavioral health and CNS/neurological/neuropsychological performance measures and domains of relevance to exploration class missions?
GapBMed-103: What are the validated, efficacious treatments (individual or Team-based) and/or countermeasures to prevent adverse behavioral conditions, CNS/neurological, and/or psychiatric disorders caused by either single and/or integrated exposures to spaceflight hazards during exploration class missions?
GapBMed-104: Given the potentially negative spaceflight associated CNS changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated modifications to habitat/vehicle to mitigate stressors impacting on CNS / cognition / behavioral health?
GapBMed-105: Given the potentially negative spaceflight associated CNS/cognitive changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated medical or dietary countermeasures to mitigate stressors impacting on CNS / cognition / behavioral health?
You are here!TaskCenter for Medical Countermeasures II – Cross Risk

RiskRisk of Cardiovascular Disease and Other Degenerative Tissue Effects From Radiation Exposure and Secondary Spaceflight Stressors
You are here!TaskCenter for Medical Countermeasures II – Cross Risk

RiskRisk of Radiation Carcinogenesis
You are here!TaskCenter for Medical Countermeasures II – Cross Risk

RiskRisk of Spaceflight Induced Cardiovascular Disease
You are here!TaskCenter for Medical Countermeasures II – Cross Risk